PUMA BIOTECHNOLOGY, INC. Sublease Income
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Sublease Income of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. sublease income for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. sublease income for the quarter ending 2026-03-31 was $200.00K, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. sublease income for the quarter ending 2025-06-30 was $200.00K.
- PUMA BIOTECHNOLOGY, INC. sublease income for the quarter ending 2025-03-31 was $200.00K.
- PUMA BIOTECHNOLOGY, INC. sublease income for fiscal 2023 was $500.00K, a 0.00% change from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. sublease income for fiscal 2022 was $500.00K, a 0.00% change from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. sublease income for fiscal 2021 was $500.00K, a 25.00% increase from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. sublease income for fiscal 2020 was $400.00K, a 100.00% increase from fiscal 2019.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $200.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-06 | $300.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $300.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-02 | $200.00K derived: sum of 2 quarters · filed 2023-11-02 | $300.00K 10-Q · filed 2023-11-02 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-03 | $200.00K 10-Q · filed 2023-08-03 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-04 | $300.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $300.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-03 | $200.00K derived: sum of 2 quarters · filed 2022-11-03 | $300.00K 10-Q · filed 2022-11-03 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-04 | $200.00K 10-Q · filed 2022-08-04 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-04 | $300.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $300.00K derived: sum of 2 quarters · filed 2024-02-29 | $400.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-04 | $200.00K derived: sum of 2 quarters · filed 2021-11-04 | $300.00K 10-Q · filed 2021-11-04 | $400.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $100.00K 10-Q · filed 2021-08-05 | $200.00K 10-Q · filed 2021-08-05 | $300.00K derived: sum of 3 quarters · filed 2023-03-02 | $400.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $100.00K 10-Q · filed 2021-05-06 | $200.00K derived: sum of 2 quarters · filed 2023-03-02 | $300.00K derived: sum of 3 quarters · filed 2023-03-02 | $400.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $200.00K derived: sum of 2 quarters · filed 2023-03-02 | $300.00K derived: sum of 3 quarters · filed 2023-03-02 | $400.00K 10-K · filed 2023-03-02 |
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-05 | $200.00K derived: sum of 2 quarters · filed 2020-11-05 | $300.00K 10-Q · filed 2020-11-05 | $400.00K derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-06 | $200.00K 10-Q · filed 2020-08-06 | $300.00K derived: sum of 3 quarters · filed 2022-03-03 | $400.00K derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $100.00K 10-Q · filed 2020-05-07 | $200.00K derived: sum of 2 quarters · filed 2022-03-03 | $300.00K derived: sum of 3 quarters · filed 2022-03-03 | |
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $200.00K derived: sum of 2 quarters · filed 2022-03-03 | $200.00K 10-K · filed 2022-03-03 | |
| 2019-09-30 | $100.00K 10-Q · filed 2019-11-07 | $100.00K 10-Q · filed 2019-11-07 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |